We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Reply to: The Association Between Cognitive Decline and Bone Loss and Fracture Risk Is Not Affected by Medication With Anticholinergic Effect.
- Authors
Bliuc, Dana; Tran, Thach; Adachi, Jonathan D.; Atkins, Gerald J.; Berger, Claudie; van den Bergh, Joop; Cappai, Roberto; Eisman, John A; van Geel, Tineke; Geusens, Piet; Goltzman, David; Hanley, David A; Josse, Robert; Kaiser, Stephanie; Kovacs, Christopher S.; Langsetmo, Lisa; Prior, Jerilynn C; Nguyen, Tuan V; Solomon, Lucian B.; Stapledon, Catherine
- Abstract
To the Editors: We are grateful to Dr. Naharci for the interest in our study reporting the association between cognitive decline and bone loss and fracture risk. SP ( sp 1 SP ) sp We agree that bisphosphonates (BPs) have a proven effect on reducing bone loss and fracture risk. SP ( sp 2 SP ) sp Medication with anticholinergic (ACH) side effects may also affect cognitive function as well as propensity to fall and fracture, although these effects have not been demonstrated in all studies. SP ( sp 3 SP ) sp We did not include these medication classes in our models because in observational studies the relationship between medication and outcomes is likely driven by factors associated with medication use. Importantly, the magnitude of association between bone loss and cognitive decline remained unchanged after BP and ACH medication adjustments (adjusted rate of bone loss 6.49% [95% CI, 3.17% to 9.92%] versus 6.43% [95% CI, 3.11% to 9.86%] for the original multivariable model and original multivariable model with medication).
- Subjects
PROPORTIONAL hazards models; COGNITION disorders; PARASYMPATHOLYTIC agents; PROPENSITY score matching; BONE fractures
- Publication
Journal of Bone & Mineral Research, 2022, Vol 37, Issue 5, p1075
- ISSN
0884-0431
- Publication type
Article
- DOI
10.1002/jbmr.4530